DJIA 17,810.06 91.06 0.51%
NASDAQ 4,712.97 11.10 0.24%
S&P 500 2,063.50 10.75 0.52%
market minute promo

Gilead Sciences (NASDAQ: GILD)

100.58 -0.01 (-0.01%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $100.58 -0.01%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $102.21
Previous Close $100.59
Daily Range $100.08 - $102.51
52-Week Range $63.50 - $116.83
Market Cap $151.7B
P/E Ratio 17.84
Dividend (Yield) $0.00 (0.0%)
Volume 16,742,143
Average Daily Volume 16,774,421
Current FY EPS $7.93

Sector

Healthcare

Industry

Drugs

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary Rss Feed

This May Be the Fastest Growing Big Biotech Stock Next Year (Hint: It's Not Gilead Sciences)

Analysts expect that Celgene Corporation will deliver greater earnings per share growth than Gilead Sciences in 2015.

This Time I Really Mean It

5 Health Care Stocks That Need to Play Serious Catch Up

Gilead to Buy Knight Therapeutics' Priority Review Voucher - Analyst Blog

Notable ETF Inflow Detected - VTI, BAC, GILD, INTC

Biotech's 3 Most Influential CEOs

Top Motley Fool analysts weigh in on who they think are biotech's biggest power brokers.

CNBC's Stock Pops & Drops From November 19

Gilead Gains on Harvoni's EU Approval for HCV Treatment - Analyst Blog

Gilead Gains on Harvoni's EU Approval for HCV Treatment - Analyst Blog

Why We're Huge Fans Of Gilead

Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst

Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog

See More GILD News...

GILD's Top Competitors

GILD $100.58 (-0.01%)
Current stock: GILD
AMGN $162.81 (0.08%)
Current stock: AMGN
$0.00 (0.00%)
Current stock:
BIIB $303.55 (1.49%)
Current stock: BIIB